Background: Managing pediatric refractory overactive bladder (OAB) is challenging when standard medications fail. While intradetrusor onabotulinumtoxinA (BTX-A) is a key alternative, patient response varies significantly. This case seires study evaluated the short-term efficacy of BTX-A in the treatment of refractory OAB pediatric patients.
Methods: We conducted a case series study of 6 children (aged 10–16 years) with refractory OAB treated with intradetrusor BTX-A. For each patient we assessed several outcomes including the resolution of urinary incontinence and hydronephrosis, post-void residual (PVR) volumes, and a qualitative assessment of QoL at a 3-month follow-up.
Results: Five out of six patients (83.3%) were classified as responders, achieving complete significant bladder capacity increase, clinical dryness and resolution of baseline hydronephrosis. These patients reported significant improvements in school and social participation. One patient, characterized by the longest duration of symptoms (7 years), remained non-responsive and showed only minor improvement in the bladder capacity. Safety monitoring showed that PVR volumes remained within acceptable limits for all patients, with no cases of persistent urinary retention.
Conclusion: Intradetrusor BTX-A is a safe and highly effective intervention for pediatric patients with refractory OAB. More evidence is required to fully explore its long-term efficacy and safety.
|
